Proficio Capital Partners LLC Buys New Shares in United Therapeutics Co. (NASDAQ:UTHR)

Proficio Capital Partners LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the 4th quarter, Holdings Channel reports. The institutional investor bought 64,217 shares of the biotechnology company’s stock, valued at approximately $22,658,000.

Several other large investors have also recently bought and sold shares of UTHR. Milestone Asset Management LLC increased its position in shares of United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 1,037 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in shares of United Therapeutics by 9.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock valued at $3,326,000 after buying an additional 789 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in United Therapeutics by 35.4% during the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after buying an additional 50,291 shares during the last quarter. Franklin Resources Inc. increased its holdings in United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after buying an additional 123,929 shares during the last quarter. Finally, Burney Co. raised its position in United Therapeutics by 113.3% during the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock worth $8,441,000 after acquiring an additional 12,705 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total value of $2,882,649.00. Following the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 124,164 shares of company stock worth $45,278,893 in the last quarter. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

UTHR opened at $319.96 on Friday. The business has a fifty day simple moving average of $359.65 and a 200 day simple moving average of $360.71. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The company has a market capitalization of $14.28 billion, a PE ratio of 14.05, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. During the same quarter in the previous year, the business posted $4.36 earnings per share. Equities analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of analyst reports. UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research report on Thursday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.